Randomized Phase II Study of Sorafenib With or Without Everolimus in Patients With Radioactive Iodine Refractory Hurthle Cell Thyroid Cancer
Phase of Trial: Phase II
Latest Information Update: 23 Jun 2017
At a glance
- Drugs Everolimus (Primary) ; Sorafenib
- Indications Thyroid cancer
- Focus Therapeutic Use
- 16 Nov 2016 Planned number of patients changed from 56 to 34.
- 24 Sep 2015 Planned primary completion date changed from 1 Jul 2020 to 1 Aug 2020 as reported by ClinicalTrials.gov record.
- 03 Aug 2015 Planned primary completion date changed from 1 Oct 2016 to 1 Jul 2020 as reported by ClinicalTrials.gov record.